March Gladness: Vitae Rebounds With Reassuring Data In Psoriasis
This article was originally published in The Pink Sheet Daily
Vitae's first-in-class ROR gamma t inhibitor shows significant reduction of PASI scores with two doses tested in Phase IIa, and a solid safety profile, despite some liver enzyme increases with the higher dose.
You may also be interested in...
The drug-discovery specialist is mulling several potential partners for its ROR gamma t inhibitor program, which has potential in autoimmune indications. Two cash-generating deals with Boehringer Ingelheim have made the clinical-stage company self-sufficient for nearly a decade.
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.